ViVerita Therapeutics
Precision oncology targets to develop transformative, patient-tailored cancer therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| Total Funding | 000k | ||
Related Content
ViVerita Therapeutics is at the forefront of precision oncology, focusing on developing next-generation therapies that address the complexity and heterogeneity of cancer. The company is driven by patient needs and aims to discover novel therapeutic targets, creating medicines that are both effective and safe. ViVerita operates in the healthcare sector, specifically targeting cancer treatment, and serves patients who require personalized medical solutions. The business model revolves around cutting-edge scientific research and business excellence, leveraging advanced genetic screening techniques in genetically engineered mouse models to identify new drug targets. Revenue is generated through the development and potential commercialization of these transformative therapies. The company is supported by a team of experts, including Dr. Daniel Schramek, a leader in functional cancer genomics, who contributes to the identification of genotype-specific vulnerabilities in various cancers. ViVerita's commitment to precision and innovation positions it as a key player in the oncology market.
Keywords: precision oncology, cancer therapies, patient-tailored, therapeutic targets, genetic screening, drug development, healthcare, cancer treatment, personalized medicine, genomics.